BNP PARIBAS ARBITRAGE/PUT/MODERNA/100/0.01/20.12.24 | Market Closed - Borsa Italiana 04:04:59 2024-07-12 pm EDT | ||
| 0.0825 EUR | +2.48% |
|
| Current month | -1.89% | ||
| 1 month | +100.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.078 | -3.11% |
| 24-07-11 | 0.0805 | -12.50% |
| 24-07-10 | 0.092 | -2.65% |
| 24-07-09 | 0.0945 | +4.42% |
| 24-07-08 | 0.0905 | +9.70% |
Real-time Borsa Italiana
Last update July 12, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P216B5 | |
| ISIN | NLBNPIT216B5 |
| Date issued | 2024-03-26 |
| Strike | 100 $ |
| Maturity | 2024-12-20 (161 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.1605 € |
|---|---|
| Lowest since issue | 0.0285 € |
| Spread | 0.003 € |
| Spread % | 3.55% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.12%
- Stock Market
- Warrants
- P216B5 Warrant
